Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Barr Seeks FDA Approval Of Low-Dose Extended-Cycle Contraceptive Lo Seasonique

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA grants Lo Seasonique an Oct. 24 action date.

You may also be interested in...

Lybrel To Launch In July Following FDA Approval

Wyeth’s oral contraceptive is the first continuous-use product without a placebo phase or pill-free interval.

Changing Of The Seasonale: Barr’s Extended-Cycle Contraceptive Goes Generic

Company tries to hedge losses through “authorized” generic and follow-on Seasonique.

Farxiga CKD Trial Stopped Early For Efficacy, Giving The SGLT2 Inhibitor An Edge

A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts